Table 2.
Adverse event | Grade 1, 2 (%) | Grade 3 (%) | Grade 4 (%) |
---|---|---|---|
Anemia | 7 (18) | 3 (8) | |
Chills | 2 (5) | ||
Fatigue | 13 (34) | 2 (5) | |
Fever | 3 (8) | 1 (3) | |
Gait disturbance | 2 (5) | ||
Limb edema | 3 (8) | ||
Acneiform rash | 3 (8) | ||
Maculo-papular rash | 2 (5) | ||
Constipation | 2 (5) | ||
Dry mouth | 2 (5) | ||
Oral mucositis | 2 (5) | ||
Nausea | 8 (21) | 1 (3) | |
Vomiting | 8 (21) | ||
Ileal obstruction | 1 (3) | ||
Allergic reaction | 2 (5) | ||
Alanine aminotransferase Increase | 4 (11) | ||
Alkaline phosphatase Increase | 5 (13) | 1 (3) | |
Aspartate aminotransferase Increase | 10 (26) | 1 (3) | |
Bilirubin increase | 3 (8) | ||
Creatinine increase | 3 (8) | ||
Lymphocyte count decrease | 2 (5) | 1 (3) | |
Neutrophil count decrease | 3 (8) | 1 (3) | |
Platelet count decrease | 10 (26) | 2 (5) | |
Weight loss | 3 (8) | ||
White blood cell decrease | 4 (11) | ||
Anorexia | 5 (13) | 1 (3) | |
Myalgia | 2 (5) | ||
Generalized muscle weakness | 3 (8) | ||
Headache | 4 (11) | ||
Peripheral motor neuropathy | 2 (5) | ||
Peripheral sensory neuropathy | 4 (11) | ||
Cough | 3 (8) | ||
Epistaxis | 3 (8) | 1 (3) | |
Hypoxia | 1 (3) | ||
Muscle weakness lower limb | 1 (3) | ||
Dehydration | 2 (3) | ||
Investigations: Other, specify | 1 (3) | 1 (3) | |
Urinary tract infection | 1 (3) | ||
Upper respiratory infection | 1 (3) | ||
Diarrhea | 1 (3) | ||
Blurred vision | 1 (3) | ||
Total worst degree | 20 (58) | 11 (16) | 0 (0) |
Includes specific adverse events with at least two grade 1 or 2 events or 1 grade 3 event. Total worst degree includes all treatment-related adverse events.